$0.0829
Last update: Dec 31, 7:00 PM
Comments
Loading...
Spruce Biosciences Analyst Ratings and Price Targets | OTC:SPRB | Benzinga
Spruce Biosciences Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Spruce Biosciences Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
JMP Securities
Leerink Partners
SVB Leerink
Credit Suisse
1calculated from analyst ratings
Analyst Ratings for Spruce Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/16/2025 | Buy Now | — | RBC Capital | Gregory Renza48% | $1.5 → $0.5 | Maintains | Sector Perform | Get Alert |
| 12/16/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | — | Reiterates | Neutral → Neutral | Get Alert |
| 12/12/2024 | Buy Now | — | Guggenheim | Evan Wang8% | — | Reiterates | Neutral → Neutral | Get Alert |
| 12/11/2024 | Buy Now | — | JMP Securities | Jonathan Wolleben68% | $3 → $3 | Downgrade | Market Outperform → Market Perform | Get Alert |
| 12/11/2024 | Buy Now | — | RBC Capital | Gregory Renza48% | $2 → $1.5 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 12/11/2024 | Buy Now | — | Oppenheimer | Hartaj Singh47% | — | Downgrade | Outperform → Perform | Get Alert |
| 11/12/2024 | Buy Now | — | RBC Capital | Gregory Renza48% | $2 → $2 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 08/19/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | — | Reiterates | → Neutral | Get Alert |
| 08/13/2024 | Buy Now | — | RBC Capital | Gregory Renza48% | $2 → $2 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 06/13/2024 | Buy Now | — | Oppenheimer | Hartaj Singh47% | $4 → $3 | Maintains | Outperform | Get Alert |
| 06/05/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | — | Reiterates | → Neutral | Get Alert |
| 05/14/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | — | Reiterates | → Neutral | Get Alert |
| 03/14/2024 | Buy Now | — | RBC Capital | Gregory Renza48% | $9 → $2 | Downgrade | Outperform → Sector Perform | Get Alert |
| 03/14/2024 | Buy Now | — | JMP Securities | Jonathan Wolleben68% | $8 → $3 | Maintains | Market Outperform | Get Alert |
| 03/14/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | — | Downgrade | Buy → Neutral | Get Alert |
| 03/14/2024 | Buy Now | — | Leerink Partners | Joseph Schwartz65% | $9 → $2 | Downgrade | Outperform → Market Perform | Get Alert |
| 03/14/2024 | Buy Now | — | Ladenburg Thalmann | Aydin Huseynov34% | — | Downgrade | Buy → Neutral | Get Alert |
| 03/14/2024 | Buy Now | — | Guggenheim | Evan Wang8% | — | Downgrade | Buy → Neutral | Get Alert |
| 03/05/2024 | Buy Now | — | RBC Capital | Gregory Renza48% | $9 → $9 | Reiterates | Outperform → Outperform | Get Alert |
| 02/26/2024 | Buy Now | — | RBC Capital | Gregory Renza48% | $8 → $9 | Maintains | Outperform | Get Alert |
| 02/21/2024 | Buy Now | — | Guggenheim | Evan Wang8% | → $10 | Initiates | → Buy | Get Alert |
| 11/20/2023 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | → $10 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | — | RBC Capital | Gregory Renza48% | → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 09/13/2023 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | → $10 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | Buy Now | — | SVB Leerink | Joseph Schwartz65% | $3 → $9 | Upgrade | Market Perform → Outperform | Get Alert |
| 08/18/2023 | Buy Now | — | Oppenheimer | Hartaj Singh47% | $8 → $7 | Maintains | Outperform | Get Alert |
| 08/18/2023 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/16/2023 | Buy Now | — | JMP Securities | Jonathan Wolleben68% | $7 → $8 | Maintains | Outperform | Get Alert |
| 08/15/2023 | Buy Now | — | RBC Capital | Gregory Renza48% | → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 06/13/2023 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2023 | Buy Now | — | Oppenheimer | Hartaj Singh47% | → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 05/16/2023 | Buy Now | — | RBC Capital | Gregory Renza48% | → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 05/16/2023 | Buy Now | — | JMP Securities | Jonathan Wolleben68% | → $7 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/16/2023 | Buy Now | — | Credit Suisse | Tiago Fauth42% | → $4 | Reiterates | Outperform → Outperform | Get Alert |
| 03/23/2023 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | $20 → $10 | Maintains | Buy | Get Alert |
| 03/20/2023 | Buy Now | — | RBC Capital | Gregory Renza48% | → $8 | Reiterates | → Outperform | Get Alert |
| 03/17/2023 | Buy Now | — | JMP Securities | Jonathan Wolleben68% | → $7 | Maintains | Market Outperform | Get Alert |
| 03/17/2023 | Buy Now | — | Credit Suisse | Tiago Fauth42% | → $4 | Reiterates | → Outperform | Get Alert |
| 02/13/2023 | Buy Now | — | RBC Capital | Gregory Renza48% | $9 → $8 | Maintains | Outperform | Get Alert |
| 01/08/2023 | Buy Now | — | JMP Securities | Jonathan Wolleben68% | $8 → $8 | Maintains | Outperform | Get Alert |
| 11/17/2022 | Buy Now | — | Oppenheimer | Hartaj Singh47% | $13 → $8 | Maintains | Outperform | Get Alert |
| 11/16/2022 | Buy Now | — | JMP Securities | Jonathan Wolleben68% | → $8 | Initiates | → Market Outperform | Get Alert |
FAQ
What is the target price for Spruce Biosciences (SPRB) stock?
The latest price target for Spruce Biosciences (OTCPK:SPRB) was reported by RBC Capital on April 16, 2025. The analyst firm set a price target for $0.50 expecting SPRB to fall to within 12 months (a possible NaN% downside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Spruce Biosciences (SPRB)?
The latest analyst rating for Spruce Biosciences (OTCPK:SPRB) was provided by RBC Capital, and Spruce Biosciences maintained their sector perform rating.
When was the last upgrade for Spruce Biosciences (SPRB)?
The last upgrade for Spruce Biosciences Inc happened on September 8, 2023 when SVB Leerink raised their price target to $9. SVB Leerink previously had a market perform for Spruce Biosciences Inc.
When was the last downgrade for Spruce Biosciences (SPRB)?
The last downgrade for Spruce Biosciences Inc happened on December 11, 2024 when JMP Securities changed their price target from $3 to $3 for Spruce Biosciences Inc.
When is the next analyst rating going to be posted or updated for Spruce Biosciences (SPRB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Spruce Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Spruce Biosciences was filed on April 16, 2025 so you should expect the next rating to be made available sometime around April 16, 2026.
Is the Analyst Rating Spruce Biosciences (SPRB) correct?
While ratings are subjective and will change, the latest Spruce Biosciences (SPRB) rating was a maintained with a price target of $1.50 to $0.50. The current price Spruce Biosciences (SPRB) is trading at is $undefined, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
